FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

188 letters match. Newest first.

  1. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  2. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  3. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  4. Owen Biosciences, Inc.

    Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

    High risk
  5. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  6. Seema International

    FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.

    High risk
  7. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  8. Apotex Inc.

    FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

    High risk
  9. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  10. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  11. The Tranzonic Companies/Innocore Sales & Marketing Inc.

    FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

    High risk
  12. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  13. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  14. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  15. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  16. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  17. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  18. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  19. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  20. Meds For Vets, LLC

    Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.

    High risk
  21. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk
  22. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  23. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  24. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  25. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  26. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  27. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  28. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  29. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  30. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  31. Pushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi

    FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.

    High risk
  32. Kenil Healthcare Private Limited

    FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.

    High risk
  33. Horizon Tool Inc.

    FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.

    High risk
  34. Evi Labs LLC

    FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.

    High risk
  35. Zhejiang Easyclean Daily Chemical Co., Ltd

    FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.

    High risk
  36. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  37. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  38. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk
  39. Skye Biologics Holdings LLC

    FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.

    High risk
  40. Mentha & Allied Products Private Ltd.

    FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

    High risk
  41. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  42. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  43. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  44. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  45. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  46. PMS4PMS, LLC

    FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.

    High risk
  47. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  48. Aspen Biopharma Labs Private Limited

    FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.

    High risk
  49. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  50. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk